1. Home
  2. WVE vs ARDX Comparison

WVE vs ARDX Comparison

Compare WVE & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • ARDX
  • Stock Information
  • Founded
  • WVE 2012
  • ARDX 2007
  • Country
  • WVE Singapore
  • ARDX United States
  • Employees
  • WVE N/A
  • ARDX N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • ARDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • WVE Health Care
  • ARDX Health Care
  • Exchange
  • WVE Nasdaq
  • ARDX Nasdaq
  • Market Cap
  • WVE 915.6M
  • ARDX 971.4M
  • IPO Year
  • WVE 2015
  • ARDX 2014
  • Fundamental
  • Price
  • WVE $7.22
  • ARDX $3.68
  • Analyst Decision
  • WVE Strong Buy
  • ARDX Strong Buy
  • Analyst Count
  • WVE 11
  • ARDX 8
  • Target Price
  • WVE $20.91
  • ARDX $10.19
  • AVG Volume (30 Days)
  • WVE 1.1M
  • ARDX 5.0M
  • Earning Date
  • WVE 05-08-2025
  • ARDX 07-31-2025
  • Dividend Yield
  • WVE N/A
  • ARDX N/A
  • EPS Growth
  • WVE N/A
  • ARDX N/A
  • EPS
  • WVE N/A
  • ARDX N/A
  • Revenue
  • WVE $104,939,000.00
  • ARDX $361,706,000.00
  • Revenue This Year
  • WVE N/A
  • ARDX $12.01
  • Revenue Next Year
  • WVE N/A
  • ARDX $34.66
  • P/E Ratio
  • WVE N/A
  • ARDX N/A
  • Revenue Growth
  • WVE N/A
  • ARDX 127.33
  • 52 Week Low
  • WVE $4.25
  • ARDX $3.21
  • 52 Week High
  • WVE $16.74
  • ARDX $8.06
  • Technical
  • Relative Strength Index (RSI)
  • WVE 61.17
  • ARDX 41.94
  • Support Level
  • WVE $5.98
  • ARDX $3.62
  • Resistance Level
  • WVE $6.30
  • ARDX $3.97
  • Average True Range (ATR)
  • WVE 0.33
  • ARDX 0.22
  • MACD
  • WVE 0.14
  • ARDX 0.01
  • Stochastic Oscillator
  • WVE 92.21
  • ARDX 15.71

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: